International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 4.14.2022
researchers in a lab
generic pharmacy photo
First Generic Revlimid (lenalidomide) Launched
On March 7, 2022, Teva Pharmaceuticals announced the launch of the first generic version of REVLIMID® (lenalidomide) in the U.S. — leading to many questions from the myeloma community. In his blog, IMF Chairman of the Board Dr. Brian G.M. Durie discusses developing information on generic lenalidomide — what is known and what is currently unknown as well as details that are still unfolding. The IMF will continue to diligently pursue more definitive information about this recent development and will be providing updates as they become available. Any feedback from patients, who have been prescribed generic lenalidomide, will be greatly appreciated.
2020BlogButton.png
Dr Joe facebook promotion
Facebook Live: IMF Chief Medical Officer Dr. Joseph Mikhael on April 19
Join us on April 19, Tuesday @ 4:00 p.m. PT / 7:00 p.m. ET as IMF Chief Medical Officer Dr. Joseph Mikhael goes LIVE on Facebook to address disparities in multiple myeloma and the path to health equity. Dr. Mikhael will discuss disparities in myeloma treatment and diagnosis, representation in clinical trials, the importance of achieving health equity, and what actions are being taken to do so. Join this insightful 30-minute live event for FREE by visiting https://www.facebook.com/myeloma on the scheduled time and date. You can participate in our online community by liking the IMF's Facebook page.
Visit Us Button
ons banner 2022 email
Nurses: Register NOW for the IMF 1.5 CNE Symposium at ONS 2022
The IMF 1.5 CNE Symposium, “New Drugs, Regimens, and Strategies for Multiple Myeloma: Case Studies for Nurses” at ONS 2022 will be held on Thursday, April 28 from 12:15 p.m. — 1:45 p.m. PST in Anaheim, CA. Four highly experienced nurses will share their expertise using real-life patient case scenarios with a focus on clinical pearls and practical solutions. Both experienced and new oncology nurses will find helpful nursing insights and take-home tools to implement and share with patients and colleagues.
register button
amazon smile for mothers day
This Mother’s Day, Shop AmazonSmile and Give to the IMF!
When you shop at smile.amazon.com and designate the International Myeloma Foundation (IMF) as your preferred charity, Amazon donates 0.5% of all purchases you make to the IMF, at no added cost to you. Make this Mother’s Day special by shopping at AmazonSmile while giving to the IMF at the same time!
2020ButtonShopNow.png
ask doctor durie video image with revlimid question
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
Is a generic version of Revlimid® available?
Watch Now
 
Online Patient Forum

Smart Patients: Join the Conversation
Clinical Trial Fact Sheets

CANOVA Trial (Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Upcoming Events

Register Now
14th Annual Miles for Myeloma 5K Run/Walk

Register Now
14th Annual Czerkies Memorial Golf Outing

Learn More
Grand Tour of Scotland Whisky Tasting
Webinar Replays
Watch the Replay
Regional Community Workshop — West South Central

Watch the Replay
Regional Community Workshop — Tri-State

Watch the Replay
Are Side Effects Impacting Your Quality of Life?

See also, all of our events.
 

We Thank Our Sponsors:

Amgen, Bristol Myers Squibb, GSK, and Karyopharm Therapeutics
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
2020ButtonDonateBurg.png
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma

www.myeloma.org
This email was sent by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page